BiotechTube

Pelacarsen (TQJ230) 80mg + Matching placebo

Phase 2Recruiting
0 watching 0 views this week⚡ Active
52
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Aortic Stenosis

Conditions

Aortic Stenosis

Trial Timeline

Mar 7, 2024 → Mar 12, 2030

NCT ID
NCT05646381

About Pelacarsen (TQJ230) 80mg + Matching placebo

Pelacarsen (TQJ230) 80mg + Matching placebo is a phase 2 stage product being developed by Novartis for Aortic Stenosis. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05646381. Target conditions include Aortic Stenosis.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT05646381Phase 2Recruiting

Competing Products

20 competing products in Aortic Stenosis

See all competitors
ProductCompanyStageHype Score
Apixaban 5 MG + Apixaban 2.5 MG + WarfarinArtivionPhase 3
72
EdoxabanDaiichi SankyoPhase 3
77
NOAC + DAPTDaiichi SankyoApproved
85
Ticagrelor + PlaceboAstraZenecaPhase 2
52
Rosuvastatin + PlaceboAstraZenecaPhase 3
77
candesartan + placeboAstraZenecaPhase 3
77
SugammadexMerckApproved
85
bisoprolol + placeboMerckApproved
85
Metformin Glucophage 500mg (IR) tablets M90 + Placebo Oral TabletMerckPhase 2/3
65
fluvastatinNovartisPhase 2
52
ACZ885 + PlaceboNovartisPhase 2
52
Evolocumab + PlaceboAmgenPhase 1
32
atorvastatin (Lipitor)PfizerApproved
84
Apixaban + Standard of carePfizerPhase 3
76
Ataciguat + PlaceboSanofiPhase 1
32
Ataciguat (HMR1766)SanofiPhase 2
51
Haemocomplettan® P + Saline solutionCSLPhase 2
51
Rivaroxaban (Xarelto, BAY59-7939) + Acetylsalicylic Acid (ASA) + Clopidogrel + Rivaroxaban (Xarelto, BAY59-7939) + Vitamin K antagonist (VKA)BayerPhase 3
74
Acetylsalicylic acid + Clopidogrel + RivaroxabanBayerPhase 3
74
DesfluraneBaxterApproved
82

Other Products from Novartis

LCZ696Approved
85
zoledronic acidApproved
85
NateglinideApproved
85
TenofovirApproved
85
FTY720Approved
85